Bordetella pertussis is the causative agent of whooping cough, a particularly severe disease of infants characterized by repeated bouts of paroxysmal coughing. Until recently, this disease has been controlled through vaccination. However, mounting concerp about side effects associated with immunization with heat-killed, whole-cell vaccine preparations has lead to decreased vaccine acceptability and a disturbing rise in the incidence of the disease in recent years. There is, therefore, an urgent need to develop new, nonreactogenic, and effective vaccines against pertussis.
Virulence factors produced by B. pertussis that are candidates for inclusion in new generation vaccines include pertussis toxin (PT) and filamentous hemagglutinin (FHA) (22) . The importance of these antigens as vaccine components has been emphasized in several animal models (11, 19) . Unfortunately, human trials with acellular vaccine preparations composed of both of these components failed to elicit a fully efficacious response despite their ability to induce humoral immunity (1, 16, 34) .
Antipertussis vaccination has traditionally employed an intramuscular route, mainly stimulating a systemic response. An alternative approach would be to stimulate an immune response directly at the lung epithelial surface. This would have the additional benefit of helping to reduce B. pertussis. colonization. We have recently demonstrated that the stimulation of gut immunity by using recombinant vaccine carrier strains of Salmonella typhimurium and invasive Escherichia coli expressing plasmid-encoded FHA results in the production of specific mucosal immunity at the lung epithelial ORAL PERTUSSIS TOXIN Si SUBUNIT VACCINE 4261 agar base (Difco) supplemented with 1% glycerol and 15% (vol/vol) defibrinated horse blood or in SS-X broth (33) . Antibiotics were used at the following concentrations: ampicillin, 100 p,g/ml; tetracycline, 50 p,g/ml; and kanamycin, 50 ,ug/ml. Broth cultures were aerated by shaking at 300 rpm in a New Brunswick Environmental Incubator Shaker.
DNA manipulations, plasmid transfer, and induction experiments. Restriction endonucleases and T4 DNA ligase were used as previously described (25) . Plasmid isolation and transformation were performed as described by Sambrook et al. (25) . Taq polymerase was used as described by Scharf (30) . The polymerase chain reaction primers S1-5'NdeI (5'-GGCATA3XCGTTGCACTCGGGCAATT-3') and S1-3'XbaI (5'-CCAGGTCTAGAACGAATA-3') used for cloning the Si subunit cistron as a NdeI-XbaI fragment (NdeI and XbaI sites, respectively, are underlined) were synthesized with an Applied Biosystems Model 380B DNA synthesizer in accordance with the manufacturer's instructions.
Conjugal transfer of pWR110 (Kmr) to E. coli CAG629 was accomplished by using the mobilizing helper plasmid R64-drdll (Tcr) as previously described by Sansonetti et al. (27, 28) . Induction experiments were performed as previously described by Guzmain et al. (7) . Sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE) of wholecell extracts was performed as described by Laemmli (12) .
Electron microscopy. For postembedding labelling, cells of the respective strains were fixed directly in Luria broth with a fixation solution containing 0.5% (vol/vol) formaldehyde and 0.3% (vol/vol) glutaraldehyde in phosphate-buffered saline (PBS; 0.1 M phosphate buffer, 0.9% NaCl [pH 7.0]) for 1 h on ice. After being washed with PBS containing 10 mM glycine, the samples were embedded into 1.5% (wt/vol) agar. After solidification of the agar, small cubes were cut and embedded with progressive lowering of the temperature by using Lowicryl K4M resin (23) . Immunolabelling was done with a 1:25 dilution of the purified rabbit PT-specific immunoglobulin G (IgG) antibody (200 ,ug of IgG protein per ml) (36) by incubating ultrathin sections on drops of the diluted antibody for 5 h at room temperature. After being washed with PBS, the bound antibodies were made visible with protein A-gold complexes (10-nm-diameter gold particle size, 30-min incubation time), prepared by established procedures (32 and loosely attached bacteria were removed by washing the monolayers three times with PBS. For adhesion assays, the monolayers were then stained with Giemsa solution and examined by light microscopy, and the mean number of bacteria per HI-407 cell was calculated by averaging the number of bacteria adhering to 40 cells by using light microscopy. For invasion assays, DME containing gentamicin (100 ,ug/ml) was then added; this concentration of gentamicin killed extracellular bacteria and thereby prevented any reinfection of cells. Monolayers were incubated for an additional 3-h period and then washed three times with PBS. The number of invading bacteria was determined by lysing the eukaryotic cells with the addition of 1 ml of 1% Triton X-100 (vol/vol) to each well and calculating viable counts on Luria agar plates.
Mouse immunization. Six-to seven-week-old female BALB/c mice were immunized and caged separately in groups of five. Mice were immunized according to the protocols given in Table 2 . The groups were immunized with one dose on day 0 and boosted with identical doses 30 and 40 days later. The animals were sacrificed 10 days after the last booster, and the samples were collected. For immunization with live bacteria, E. coli CAG629 and S. typhimurium SL3261 were grown in Luria broth, while S. typhi Ty2la was grown in brain heart infusion broth containing 0.001% galactose and B. pertussis Tohama I was grown in SS-X medium. An overnight liquid culture of bacteria was diluted 100-fold with broth containing an appropriate antibiotic for selection, and the fresh culture was incubated at 37°C until it reached early logarithmic phase. The cultures were centrifuged, and the bacteria were resuspended in PBS to an optical density which gave the appropriate viable count (as determined previously for each strain). For oral immunization, immediately before immunization an equal volume of 3% sodium bicarbonate in PBS (pH 8.0) was added to the suspension. Mice that had been deprived of water for 6 to 8 h were then gently fed with 50 ,ul of the bacterial suspension. For intraperitoneal (i.p.) immunizations, bacteria were suspended in PBS and, if required, were heat killed by treatment at 60°C for 30 min. Sacrificed mice were exsanguinated by cutting the brachial artery, and the serum was separated and stored at -20°C. Lung washes were collected after pertracheal cannulation and gentle washing with 0.7 ml of ice-cold PBS containing 2 mM phenylmethylsulfonyl fluoride as a protease inhibitor. About 0.5 ml of lung wash was recovered from each mouse. Lung washes were centrifuged at 3,000 x g for 5 min at 4°C to remove debris and stored at -20°C.
Immunological techniques. Monoclonal antibody E19 (36), which reacts with the S1 subunit of PT, was used in Western blot (immunoblot) experiments carried out essentially as described by Burnette (3) . Proteins were transferred to a nitrocellulose membrane by using 25 mM Tris-192 mM glycine-20% methanol (pH 8.3) as transfer buffer and a 10% solution of 0.3% low-fat milk in PBS (pH 7.4) as a blocking reagent. E19 hybridoma supernatant fluid was used as the first antibody. The detection system used was Bio-Rad horseradish peroxidase-conjugated goat anti-mouse IgG and 4-chloro-1-naphthol as substrate.
For the determination of subclass-specific antibodies against the S1 subunit in serum and lungs washes, enzymelinked immunosorbent assays (ELISAs) were performed as follows. Nunc Maxisorp Immunomodule 96-well plates were coated with PT (kindly supplied by S. Cryz) diluted in 0.1 M NaHCO3 (pH 9.6) (60 ng in 50 ,ul per well) and incubated at 4°C overnight. The wells were blocked with 100 pl of 10% 7 8 analogous sites found in pUC18 to produce pMW150. Subsequently, the Si structural gene was purified and cloned as an NdeI-EcoRI fragment into the corresponding sites of expression vector pJLA506 to construct pMW151 (Fig. 1) . This plasmid contains the Si structural gene downstream of the efficient atpE ribosome binding site and tandem lambda PL and PR promoters under the control of the temperaturesensitive cI repressor protein, i.e., under a heat-inducible expression system.
Production of rPI-S1 in Sabnonella spp. and E. coli. The expression plasmid pMW151 was transformed into the Ion and htpR protease-deficient E. coli CAG629 and S. typhimurium SL5283. Plasmid DNA isolated from the latter was used 7 8 to transform S. typhimunium SL3261 and S. typhi Ty2ia.
After induction at 42°C for 1 h, whole-cell extracts were subjected to SDS-PAGE and Western blotting with the Sl-specific monoclonal antibody E19 (36) . rPT-Si and a degradation product of rPT-Si migrating as a slightly lower band were detected at levels significantly higher than those found for B. pertussis Tohama I (Fig. 2) . Lower levels of rPT-Sl were detected in recombinant strains after induction at 37°C for 24 h (results not shown).
Immunoelectron microscopy of E. coli CAG629 and S. typhi Ty2ia containing either pJLA506 or pMW151 demonstrated that, after induction, inclusion bodies are not formed 3b261antMWccn) and that rPT-Sl is accumulated at the periphery of pMW151- 5) , and E. coli bearing strains of E. coli CAG629 and S. typhi Ty2ia (Fig.   n extract of B. 3A, B, D, and E), indicating that the leader peptide of the Si 1). Bacteria in subunit is correctly processed, as previously described (4 bearing the S. flexneii invasion plasmid pWR110, elicited anti-PT antibody responses ( Table 2 ; Fig. 4) . The i.p. immunization of mice with either 106 heat-killed B. pertussis cells or 106 live S. typhimunium SL3261(pMW151) cells induced similar, high serum and lung mucosal IgG antibody levels but insignificant amounts of IgA. However, higher IgM responses were engendered by live S. typhimunrium SL3261 (pMW151) compared with heat-killed B. pertussis after i.p. immunization (compare groups a and c in Fig. 4 ).
Oral immunization with 109 live S. typhimuinum SL3261 (pMW151), S. typhi Ty2la(pMW151), or E. coli CAG629 (pWRllO and pMW151) elicited high systemic IgG and low systemic IgA levels, similar to those levels found after i.p. immunizations (compare groups a and c with groups e, f, and h in Fig. 4A ), and elevated anti-pertussis toxin IgA levels in lung washes. The amounts of IgG and IgA in lung washes were found to be highest after oral immunization with S. typhimurium SL3261(pMW151), followed by S. typhi Ty2la (pMW151), and were lowest after immunization with E. coli CAG629(pWR110 and pMW151) (compare groups e, f, and h in Fig. 4B ). This variation may reflect strain differences in the ability to persist in mice. The absence of plasmid pWRllO from E. coli CAG629(pMW151) was associated with a marked decrease in the anti-PT response (compare groups g and h in Fig. 4) . Presumably a lack of the invasion plasmid prevents an adequate antigen presentation to the gut immune system by E. coli CAG629(pMW151). Significant IgM responses were not apparent for any strain after oral immunization (groups d to h in Fig. 4 ).
DISCUSSION
Whooping cough is a severe respiratory tract disease. Traditional antipertussis vaccination has employed the intramuscular route. However, it may be desirable to develop vaccines which stimulate not only specific serum responses but also specific IgA in the respiratoxy tract. The production of lung mucosal secretory antibodies may interfere with the attachment of B. penussis and subsequent colonization and thereby help prevent infection as well as disease. Such a vaccine would additionally favor eradication of a disease for which there is only a human reservoir. Serological studies of patients with whooping cough have revealed increases in both IgG and IgA levels against specific B. pertussis virulence determinants. On the other hand, whole-cell vaccines engender weak, if any, specific IgA (34) . The mucosal immunological network contains subpopulations of lymphoid cells with the ability to migrate from the intestine to other distant mucosa (i.e., the respiratory tract) (2, 15, 24) . Therefore, the development of enteric delivery systems for pertussis antigens which stimulate both a systemic and lung mucosal response may not only result in the prevention of infection and disease, and thus provide an attractive alternative to purified component vaccines against whooping cough, but also eliminate the need for purification of individual vaccine components for this purpose. The purification of individual vaccine components may be cost prohibitive for use in Third World countries.
We have recently demonstrated that stimulation of gut immunity by using recombinant S. typhimurium aroA SL3261 expressing the 220-kDa FHA protein resulted in a specific secretory IgA response at the lung mucosal surface (6, 7) . Another group of investigators was unsuccessful in engendering a lung mucosal immune response after oral immunization of mice with Salmonella spp. expressing truncated FHA (17, 20) . The inability to detect lung mucosal responses in these previous studies may reflect problems of plasmid instability or the expression level of recombinant FHA obtained. Our ability to detect a mucosal immune response may also have been due to an increased immunogenicity of the native protein compared with the truncated forms of FHA expressed in the earlier studies (17, 20) .
PT is considered an essential protective component for new generation vaccines against whooping cough. In our present study, rPT-Sl was expressed in the attenuated aroA mutant of S. typhimurium, SL3261, in the human typhoid vaccine strain S. typhi Ty2la, and in E. coli CAG629 containing the S. flexneri plasmid pWR110, which encodes specific to PT were detected in lung washes. These immune responses were detected irrespective of whether rPT-S1 was localized in the periplasmic space (E. coli CAG629 and S. typhi Ty2la) or in the cytoplasm (S. typhimurium SL3261).
It has been demonstrated that i.p. immunization of mice with crude preparations of recombinant Si subunit resulted in an anti-PT response, but mice were not significantly protected from intracerebral challenge (4). It will be important to determine whether oral immunization of mice with recombinant Salmonella spp. or invasive E. coli expressing rPT-Sl either alone or in conjunction with such strains expressing FHA, stimulating both systemic and lung mucosal responses, results in a protective immune response in the intranasal model of infection (21) . An immune response against the S2 to S5 subunits of the PT B oligomer may be necessary to achieve protection.
Live antigen delivery systems resistant to antibiotics are considered by the U.S. Food and Drug Administration to be unacceptable for human use. Non-antibiotic-resistance transposon systems which allow the stable integration and expression of potential vaccine components, for instance pertussis holotoxin in Bordetella bronchiseptica (35) , in antibiotic-sensitive delivery systems are, however, available (9) . Similar antibiotic-resistance "mini-transposons" have been used to successfully integrate a gene encoding the circumsporozoite protein of Plasmodium yoelii into the chromosome of S. typhimurium and elicit an immune response against the circumsporozoite protein in mice (4a) . Experiments designed to express the other PT subunits, S2 to S5, and to incorporate such expression systems into the chromosome of the vaccine delivery strains described above are in progress.
In this report, and in the previous studies made by Guzmain et al. (6, 7) , we have demonstrated the potential of recombinant enteric vaccine carrier systems to stimulate lung mucosal immune responses to B. pertussis antigens. These results may lead to the future development of oral vaccines against whooping cough and other infections of the respiratory tract. Particularly encouraging is the anti-PT response engendered by S. typhi Ty21a(pMW151), since Ty2la has been approved for human use by the U.S. Food and Drug Administration and is known to be a safe vaccine (13) . However, the apparent failure of Ty21a to engender an anti-O antigen immune response in infants by using standard doses efficacious in school children (18) indicates that alternative strains may be required as vaccine delivery vehicles for infants.
